FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310103515> ?p ?o ?g. }

• W4310103515 endingPage "9344" @default.
• W4310103515 startingPage "9342" @default.
• W4310103515 abstract "Background: Castleman disease (CD) is a heterogeneous rare disorder, characterized by lymph node enlargement with a common histopathological spectrum. This disease comprises the subtypes unicentric (UCD), HHV8-associated multicentric CD (HHV8 MCD), POEMS-associated MCD (POEMS MCD) and idiopathic multicentric CD (iMCD). Whereas UCD is a localized reversible disease, the other three subtypes are systemic diseases with multiple lymphadenopathies. The TAFRO (thrombocytopenia, anasarca, fever, reticulin myelofibrosis, organomegaly) syndrome is an aggressive form of iMCD. Each CD subtype has different clinical features, prognosis and treatment. Aims: To study a large series of patients diagnosed with CD to describe the clinical and biological characteristics, as well as the treatments and outcomes of the different CD subtypes. Methods: Multicentric retrospective study which includes patients diagnosed with different subtypes of CD in 20 Spanish hospitals from 2008 to 2022. Clinical and biological data were retrieved from the clinical records. The project was approved by the Ethical Committee of Germans Trias I Pujol Hospital (PI-20-103). Statistical analyses were performed using SPSS v24.0 (IBM, Somer, NY). Results: One hundred and forty-five patients with available data were included; 52 with UCD and 93 with any of the 3 subtypes of MCD. The median follow-up was 3.4 years. The main clinical and biological characteristics of the 4 CD subtypes are shown in table 1 and differences in OS in figure 1. Most patients with HHV-8 MCD were HIV-infected (74%), whom 78% had positive HIV load (median [range]: 85603.5 copies/mL [227, 10000000]); with median CD4 lymphocyte count 0.209x109/L (range: 0.016, 1.2) and 48% of them had concomitant or prior Kaposi's sarcoma. Three iMCD patients had TAFRO. All patients with UCD were treated with surgery. Patients with HHV-8 MCD were treated at front-line with rituximab +/- doxorubicin +/- antiviral (63%) or other treatments such as polychemotherapy +/- rituximab or steroids (37%). Patients with iMCD were treated with anti-IL-6 (27%), polychemotherapy plus rituximab (20%), rituximab alone (33%) and steroids (20%). Treatment of POEMS MCD was also diverse; 3 patients received lenalidomide plus dexamethasone, 2 polychemotherapy, 1 anti-IL-6 and 1 auto SCT (3 patients unrecorded). The results of the first-line treatments administered in each CD subtype are shown in Table 1. Eleven patients (7.6%) had concomitant or evolved lymphoma (2 UCD, 2 iMCD and 7 HHV-8 MCD). Thirty-four patients are dead (21 HHV8-MCD, 6 iMCD-TAFRO, 4 UCD, 3 POEMS), 7 of them from CD (5 HHV8-MCD, 1 iMCD-TAFRO, 1 UCD). Conclusions: Castleman Disease subtypes have different characteristics and outcomes. First-line treatment is heterogeneous in all MCD subtypes. Patients with CD have an increased risk of developing lymphoma being higher in HHV8-MCD. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal" @default.
• W4310103515 created "2022-11-30" @default.
• W4310103515 creator A5000867442 @default.
• W4310103515 creator A5000980711 @default.
• W4310103515 creator A5003221967 @default.
• W4310103515 creator A5003266843 @default.
• W4310103515 creator A5003747225 @default.
• W4310103515 creator A5006074198 @default.
• W4310103515 creator A5008759843 @default.
• W4310103515 creator A5014545445 @default.
• W4310103515 creator A5015753706 @default.
• W4310103515 creator A5034861019 @default.
• W4310103515 creator A5035549893 @default.
• W4310103515 creator A5039525330 @default.
• W4310103515 creator A5041612097 @default.
• W4310103515 creator A5042592629 @default.
• W4310103515 creator A5043986547 @default.
• W4310103515 creator A5046760522 @default.
• W4310103515 creator A5047780737 @default.
• W4310103515 creator A5051658692 @default.
• W4310103515 creator A5052850619 @default.
• W4310103515 creator A5053378528 @default.
• W4310103515 creator A5055406905 @default.
• W4310103515 creator A5055850190 @default.
• W4310103515 creator A5059482051 @default.
• W4310103515 creator A5060717908 @default.
• W4310103515 creator A5062814931 @default.
• W4310103515 creator A5070460361 @default.
• W4310103515 creator A5074540960 @default.
• W4310103515 creator A5076514135 @default.
• W4310103515 creator A5078048589 @default.
• W4310103515 creator A5078589511 @default.
• W4310103515 creator A5078868507 @default.
• W4310103515 creator A5080587560 @default.
• W4310103515 creator A5083191976 @default.
• W4310103515 creator A5084697555 @default.
• W4310103515 date "2022-11-15" @default.
• W4310103515 modified "2023-10-14" @default.
• W4310103515 title "Clinical Features and Outcome of Patients with Castleman Disease Subtypes: A Spanish Multicentric Study of 145 Patients from Geltamo" @default.
• W4310103515 doi "https://doi.org/10.1182/blood-2022-163165" @default.
• W4310103515 hasPublicationYear "2022" @default.
• W4310103515 type Work @default.
• W4310103515 citedByCount "0" @default.
• W4310103515 crossrefType "journal-article" @default.
• W4310103515 hasAuthorship W4310103515A5000867442 @default.
• W4310103515 hasAuthorship W4310103515A5000980711 @default.
• W4310103515 hasAuthorship W4310103515A5003221967 @default.
• W4310103515 hasAuthorship W4310103515A5003266843 @default.
• W4310103515 hasAuthorship W4310103515A5003747225 @default.
• W4310103515 hasAuthorship W4310103515A5006074198 @default.
• W4310103515 hasAuthorship W4310103515A5008759843 @default.
• W4310103515 hasAuthorship W4310103515A5014545445 @default.
• W4310103515 hasAuthorship W4310103515A5015753706 @default.
• W4310103515 hasAuthorship W4310103515A5034861019 @default.
• W4310103515 hasAuthorship W4310103515A5035549893 @default.
• W4310103515 hasAuthorship W4310103515A5039525330 @default.
• W4310103515 hasAuthorship W4310103515A5041612097 @default.
• W4310103515 hasAuthorship W4310103515A5042592629 @default.
• W4310103515 hasAuthorship W4310103515A5043986547 @default.
• W4310103515 hasAuthorship W4310103515A5046760522 @default.
• W4310103515 hasAuthorship W4310103515A5047780737 @default.
• W4310103515 hasAuthorship W4310103515A5051658692 @default.
• W4310103515 hasAuthorship W4310103515A5052850619 @default.
• W4310103515 hasAuthorship W4310103515A5053378528 @default.
• W4310103515 hasAuthorship W4310103515A5055406905 @default.
• W4310103515 hasAuthorship W4310103515A5055850190 @default.
• W4310103515 hasAuthorship W4310103515A5059482051 @default.
• W4310103515 hasAuthorship W4310103515A5060717908 @default.
• W4310103515 hasAuthorship W4310103515A5062814931 @default.
• W4310103515 hasAuthorship W4310103515A5070460361 @default.
• W4310103515 hasAuthorship W4310103515A5074540960 @default.
• W4310103515 hasAuthorship W4310103515A5076514135 @default.
• W4310103515 hasAuthorship W4310103515A5078048589 @default.
• W4310103515 hasAuthorship W4310103515A5078589511 @default.
• W4310103515 hasAuthorship W4310103515A5078868507 @default.
• W4310103515 hasAuthorship W4310103515A5080587560 @default.
• W4310103515 hasAuthorship W4310103515A5083191976 @default.
• W4310103515 hasAuthorship W4310103515A5084697555 @default.
• W4310103515 hasConcept C126322002 @default.
• W4310103515 hasConcept C142724271 @default.
• W4310103515 hasConcept C167135981 @default.
• W4310103515 hasConcept C2776054410 @default.
• W4310103515 hasConcept C2776548574 @default.
• W4310103515 hasConcept C2778551932 @default.
• W4310103515 hasConcept C2779134260 @default.
• W4310103515 hasConcept C2780007613 @default.
• W4310103515 hasConcept C2780076729 @default.
• W4310103515 hasConcept C2780849966 @default.
• W4310103515 hasConcept C71924100 @default.
• W4310103515 hasConcept C90924648 @default.
• W4310103515 hasConceptScore W4310103515C126322002 @default.
• W4310103515 hasConceptScore W4310103515C142724271 @default.
• W4310103515 hasConceptScore W4310103515C167135981 @default.
• W4310103515 hasConceptScore W4310103515C2776054410 @default.
• W4310103515 hasConceptScore W4310103515C2776548574 @default.
• W4310103515 hasConceptScore W4310103515C2778551932 @default.
• W4310103515 hasConceptScore W4310103515C2779134260 @default.
• W4310103515 hasConceptScore W4310103515C2780007613 @default.

• next